Genetic Variation in Metabolizing Enzyme and Transporter Genes: Comprehensive Assessment in 3 Major East Asian Subpopulations With Comparison to Caucasians and Africans

The advent of high‐throughput technologies has proven valuable in the assessment of genetic differences and their effects on drug activation, metabolism, disposition, and transport. However, most studies to date have focused on a small number of genes or few alleles, some of which are rare and therefore observed infrequently or lacked rigorous ethnic characterization, thus reducing the ability to extrapolate within and among populations. In this study, the authors comprehensively assessed the allele frequencies of 165 variants comprising 27 drug‐metabolizing enzyme and transporter (DMET) genes from 2188 participants across 3 major ethnic populations: Caucasians, Africans, and East Asians. This sample size was sufficiently large to demonstrate genetic differences among these major ethnic groups while concomitantly confirming similarities among East Asian subpopulations (Korean, Han Chinese, and Japanese). A comprehensive presentation of allele and genotype frequencies is included in the online supplement, and 3 of the most widely studied cytochrome P450 (CYP) genes, CYP2D6, CYP2C19, and CYP2C9; 2 non‐CYP enzymes, NAT1 and TMPT; and 2 transporter genes, SLCO1B1 and SLCO2B1, are presented herein according to ethnic classification.

[1]  Hong-Guang Xie,et al.  Genetic analysis of the S‐mephenytoin polymorphism in a chinese population , 1995, Clinical pharmacology and therapeutics.

[2]  C. V. D. van de Velde,et al.  Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer , 2009, Clinical Cancer Research.

[3]  L. Bertilsson,et al.  Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[4]  Jukka Corander,et al.  CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure , 2007, Pharmacogenetics and genomics.

[5]  H. McLeod,et al.  Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. , 1999, Genomics.

[6]  R. Poland,et al.  Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. , 2001, Pharmacogenetics.

[7]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[8]  L Zhang,et al.  The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies , 2008, Clinical pharmacology and therapeutics.

[9]  A. Molven,et al.  Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? , 2003, Pharmacogenetics.

[10]  S. Marsh,et al.  Cancer pharmacogenetics , 2004, British Journal of Cancer.

[11]  M. Haberl,et al.  Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations , 2006, Pharmacogenetics and genomics.

[12]  Shufeng Zhou,et al.  An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in Singapore , 2005, Drug metabolism reviews.

[13]  D. O'Connor,et al.  Human adenosine 2B receptor: SNP discovery and evaluation of expression in patients with cystic fibrosis , 2005, Pharmacogenetics and genomics.

[14]  P. O'dwyer,et al.  Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Relling,et al.  Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. , 1999, Human molecular genetics.

[16]  P. Hardenbol,et al.  Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. , 2007, Pharmacogenomics.

[17]  David E. Williams,et al.  GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO) , 2002, Drug metabolism reviews.

[18]  Jürgen Brockmöller,et al.  Clinical Consequences of Cytochrome P450 2C9 Polymorphisms , 2005, Clinical pharmacology and therapeutics.

[19]  M. Bangs,et al.  Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. , 2007, British journal of clinical pharmacology.

[20]  Shengying Qin,et al.  A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. , 2008, Genomics.

[21]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.

[22]  J. Turgeon,et al.  The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. , 2007, British journal of clinical pharmacology.

[23]  B. Giusti,et al.  Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. , 2009, The American journal of cardiology.

[24]  I. Song,et al.  Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. , 2008, Drug metabolism and pharmacokinetics.

[25]  Koujirou Yamamoto,et al.  Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study , 2005, European Journal of Clinical Pharmacology.

[26]  N. Kamatani,et al.  Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese , 2006, Pharmacogenetics and genomics.

[27]  R. Weinshilboum,et al.  Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms , 1997, Clinical pharmacology and therapeutics.

[28]  T. Edwards,et al.  Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. , 2004, Pharmacogenomics.

[29]  P. Vreken,et al.  Nomenclature for human DPYD alleles. , 1998, Pharmacogenetics.

[30]  You-Ming Li,et al.  DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU , 2007, Medical oncology.

[31]  M. Ingelman-Sundberg,et al.  A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. , 2003, British journal of clinical pharmacology.

[32]  L. D. Bradford,et al.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.

[33]  J. Xie,et al.  Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. , 2008, Pharmacogenomics.

[34]  M. Ingelman-Sundberg,et al.  Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine , 2004, European Journal of Clinical Pharmacology.

[35]  Supratim Choudhuri,et al.  Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters , 2006, International journal of toxicology.

[36]  W. Tan,et al.  CYP2J2*7 single nucleotide polymorphism in a Chinese population. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[37]  M. Feldman,et al.  Genetic Structure of Human Populations , 2002, Science.

[38]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[39]  J. R. Koehler,et al.  Modern Applied Statistics with S-Plus. , 1996 .

[40]  Kathleen M. Giacomini,et al.  Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations , 2008, Proceedings of the National Academy of Sciences.

[41]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[42]  I. Cascorbi.  Genetic basis of toxic reactions to drugs and chemicals. , 2006, Toxicology letters.

[43]  R. Kim,et al.  CYP2C9 allelic variants: ethnic distribution and functional significance. , 2002, Advanced drug delivery reviews.

[44]  D. Lewis,et al.  57 varieties: the human cytochromes P450. , 2004, Pharmacogenomics.

[45]  J. Xie,et al.  Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. , 2008, Genomics.

[46]  J. Nezu,et al.  Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. , 2002, The Journal of pharmacology and experimental therapeutics.

[47]  A. Langaney,et al.  Worldwide distribution of NAT2 diversity: Implications for NAT2 evolutionary history , 2008, BMC Genetics.

[48]  S. Higuchi,et al.  Polymorphism in human organic cation transporters and metformin action. , 2008, Pharmacogenomics.

[49]  N. Crawford,et al.  Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma , 2007, BMC Medical Genetics.

[50]  Martin R. Johnson,et al.  Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  Mark W Farmen,et al.  Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. , 2007, Clinical chemistry.

[52]  K. Giacomini,et al.  Genetic Variation in Drug Transporters in Ethnic Populations , 2008, Clinical pharmacology and therapeutics.

[53]  J. Brockmöller,et al.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.

[54]  Bradford Ld.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .

[55]  D. Hochstrasser,et al.  The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction , 2009, The Pharmacogenomics Journal.

[56]  Robert L. Tanguay,et al.  Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics , 2005, Pharmacogenetics & Genomics.

[57]  R. Kim,et al.  3‐Hydroxy‐3‐methylglutaryl–coenzyme a Reductase Inhibitors (statins) and Genetic Variability (Single Nucleotide Polymorphisms) in a Hepatic Drug Uptake Transporter: What's it all About? , 2004, Clinical pharmacology and therapeutics.

[58]  H. McLeod,et al.  The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. , 2002, Pharmacogenomics.

[59]  L. Bertilsson,et al.  Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. , 1995, Pharmacogenetics.

[60]  Ji-Young Park,et al.  Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes , 2003, Antimicrobial Agents and Chemotherapy.

[61]  Ling Ji,et al.  Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. , 2002, Clinical chemistry.

[62]  J. Buolamwini,et al.  Molecular Cloning, Characterization, and Expression in Escherichia coli of Full-length cDNAs of Three Human Glutathione S-Transferase Pi Gene Variants , 1997, The Journal of Biological Chemistry.

[63]  G. B. Smith,et al.  Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. , 1998, Carcinogenesis.

[64]  B. Meshkin,et al.  Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. , 2005, Mutation research.

[65]  Yoshiro Saito,et al.  RACIAL VARIABILITY IN HAPLOTYPE FREQUENCIES OF UGT1A1 AND GLUCURONIDATION ACTIVITY OF A NOVEL SINGLE NUCLEOTIDE POLYMORPHISM 686C> T (P229L) FOUND IN AN AFRICAN-AMERICAN , 2005, Drug Metabolism and Disposition.

[66]  L. Skoog,et al.  Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients , 2005, Breast Cancer Research.

[67]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[68]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[69]  Michel Roger,et al.  CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS , 2005, Drug Metabolism and Disposition.

[70]  J. Paulauskis,et al.  Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First‐ and Third‐generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations , 2008, Clinical pharmacology and therapeutics.

[71]  L. Teh,et al.  Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism , 2006, Journal of clinical pharmacy and therapeutics.

[72]  K. Kidd,et al.  Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips , 2007, Pharmacogenetics and genomics.

[73]  M. Eichelbaum,et al.  Genetically determined differences in drug metabolism as a risk factor in drug toxicity. , 1992, Toxicology letters.

[74]  T. Ishikawa,et al.  The genetic polymorphism of drug transporters: functional analysis approaches. , 2004, Pharmacogenomics.

[75]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[76]  S. Agrawal,et al.  Genetic affinities between endogamous and inbreeding populations of Uttar Pradesh , 2007, BMC Genetics.

[77]  A. Mrhar,et al.  Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose , 2005, The Pharmacogenomics Journal.

[78]  J. Freedman,et al.  Clopidogrel, genetics, and drug responsiveness. , 2009, The New England journal of medicine.

[79]  Magnus Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[80]  A. Morrison,et al.  Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes. , 2004, Pharmacogenomics.

[81]  M Ingelman-Sundberg,et al.  Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[82]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[83]  J. Pachecka,et al.  Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs. , 2008, Acta poloniae pharmaceutica.